skip to content
Primary navigation


Drug - Erwinaze (asparaginase Erwinia chryanthemi) [EUSA Pharma, Inc]

June 2012

Therapeutic area - Oncology

Approval criteria

  • Patient has diagnosis of acute lymphoblastic leukemia (ALL) AND has developed a severe hypersensitivity reaction during treatment with E. coli-derived asparaginase

E. coli-derived asparaginse products include Elspar (asparaginase) and Oncaspar (peg-asparagase).

Background information

NCCN guidelines recommend that patients who develop severe hypersensitivity reactions during treatment with E. coli asparaginase stop current therapy with the offending agent and switch to Erwinaze.  


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top